Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9850308
SERIAL NO

14700521

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTSIM NEUENHEIMER FELD 280 69120 HEIDELBERG 69120

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Herold-Mende, Christel Bammental, DE 7 15
Kleber, Susanne Heidelberg, DE 5 10
Krammer, Peter G Heidelberg, DE 2 10
Martin-Villalba, Ana Heidelberg, DE 7 12
Sancho-Martinez, Ignacio Heidelberg, DE 8 24
Wiestler, Benedikt Schriesheim, DE 2 10

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 26, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 26, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00